



**NICOLA NORMANNO,
MD**

Head Experimental Therapy Section, INT-Fondazione Pascale, Napoli,

Dr. Nicola Normanno is a Medical Doctor and an Oncologist. He gained experience in cell and molecular biology at the National Cancer Institute, National Institutes of Health, Bethesda MD USA, where he worked from 1990 through 1993. In 1993 he joined the National Cancer Institute of Naples “Fondazione Pascale”, Naples, Italy, where he is currently the Chairman of the Research Department and the Chief of the Pharmacogenomic Laboratory at CROM, a satellite center of the Pascale Institute.

Dr. Normanno leads a research group involved in both pre-clinical and clinical studies, with particular regard to the identification of biomarkers associated with sensitivity/resistance to target-based agents in clinical development. Dr. Normanno’s group has been one of the first to use next generation sequencing (NGS)-based techniques in clinical trials. He is also involved in clinical diagnostics and in the organization of national and international external quality assessment (EQA) schemes in molecular pathology. Dr. Normanno is the author of over 180 research articles and educational papers published in peer-reviewed journals. He is also a member of the ESMO Translational Research and Personalized Medicine working group.